AuNPs coupled with DNA probes targeting the BCR/ABL fusion gene have been developed to allow the detection of the BCR/ABL oncogene with a detection limit of 1.0 pM in B-ALL samples. This evidence concerns the gene BCR and acute lymphoblastic leukemia.